Therapeutic Effect of Antimicrobial Drugs against Experimental Infections Due to Yersinia pestis in Mice

Goto, Shinichi; Tsuji, Akiyoshi; Murai, Teiko; Nishida, Motohiro; Tsukano, Hiroko; Watanabe, Haruo

doi:10.1007/bf02490060

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of aminoglycosides, tetracyclines, fluoroquinolones, β-lactams, rifamycin, chloramphenicol, sulfonamides and ketolides has been evaluated in rodent (rat and mouse) models of plague and (less frequently) in non-human primate models of pneumonic plague ( Table 2 ) [ 17 , 52 , 56 , 61 , 63 , 69 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 ]. The resulting degree of protection against plague often varies from one animal study to another.…”

Section: Antimicrobial Chemotherapymentioning

confidence: 99%

“…Third-generation cephalosporins (ceftriaxone) were not efficacious in a mouse model of pneumonic plague [ 56 ]. A lack of in vivo efficacy of ceftriaxone and carbapenems was also reported in a mouse model of septicemic plague [ 89 ]. In contrast, Bonacorsi et al came to the opposite conclusion in a study of a mouse model of septicemic plague.…”

Section: Antimicrobial Chemotherapymentioning

confidence: 99%

See 1 more Smart Citation

Antibiotic Therapy of Plague: A Review

Sebbane

Lemaître

2021

Biomolecules

View full text Add to dashboard Cite

Plague—a deadly disease caused by the bacterium Yersinia pestis—is still an international public health concern. There are three main clinical forms: bubonic plague, septicemic plague, and pulmonary plague. In all three forms, the symptoms appear suddenly and progress very rapidly. Early antibiotic therapy is essential for countering the disease. Several classes of antibiotics (e.g., tetracyclines, fluoroquinolones, aminoglycosides, sulfonamides, chloramphenicol, rifamycin, and β-lactams) are active in vitro against the majority of Y. pestis strains and have demonstrated efficacy in various animal models. However, some discrepancies have been reported. Hence, health authorities have approved and recommended several drugs for prophylactic or curative use. Only monotherapy is currently recommended; combination therapy has not shown any benefits in preclinical studies or case reports. Concerns about the emergence of multidrug-resistant strains of Y. pestis have led to the development of new classes of antibiotics and other therapeutics (e.g., LpxC inhibitors, cationic peptides, antivirulence drugs, predatory bacteria, phages, immunotherapy, host-directed therapy, and nutritional immunity). It is difficult to know which of the currently available treatments or therapeutics in development will be most effective for a given form of plague. This is due to the lack of standardization in preclinical studies, conflicting data from case reports, and the small number of clinical trials performed to date.

show abstract